Articles On Telix Pharmaceuticals (ASX:TLX)

Highlights Tissue Repair shares tumbled over 40% on its debut on the ASX. The stock price closed 39.5% below the listing price. The wound healing medicine company raised AU$22 million in its IPO. Shares of biopharmaceutical compan...

Highlights The ASX closed 0.7 per cent lower, down 49.7 points to 7420.4. RBA Governor Philip Lowe stated that the latest data and forecasts do not warrant an increase in the cash rate in 2022. Equities in Asian markets rose while the...

Telix Pharmaceuticals (ASX:TLX) has announced that the first Australian patient has been dosed in the international NOBLE Registry.

The TGA has approved Telix Pharmaceuticals' (ASX:TLX) lead prostate cancer imaging product, Illuccix (TLX591-CDx).

Highlights This health care stock delivered robust returns for investors this year. The stock surged 9% on Tuesday after it received the nod for its cancer imaging product. The biopharma company’s shares surged 850% in the past five y...

While you were watching the Melbourne Cup the ASX retreated, the RBA hinted an interest rate hike could be coming sooner than 2024, and a new IPO gained 165%. The ASX 200 closed at 7,324 points – 0.63% down from yesterday. The best sector w...

ASX biotech shares posted a month of solid gains in October, outpacing the wider market as a whole. For instance, the S&P/ASX 300 Pharmaceuticals & Biotechnology Index (ASPBKD) climbed around 6% after a sharp decline to start the...

Highlights The ASX 200 traded 0.5% lower ahead of the RBA policy decision. Seven of 11 sectors traded in the red, while financial sector declined the most. Top losers on the ASX were IAG, Whitehaven Coal and Brickworks. Australian...

Highlights The ASX 200 was up 0.3% this morning to 7,390. IAG has reduced its profit margin guidance from 13.5%-15.5% to 10%-12%. Seven out of the 11 sectors were trading in the green, with the real estate sector gaining the most, an...

Intelicare nabs MercyCare contract for its AI sensor tech Telix scores TGA approval for prostate cancer imaging product MGC receives Israeli approval for COVID treatment dosing study   Intelicare Holdings (ASX:ICR) Intelicare jumped 35.4...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a disappointing decline. At the time of writing, the benchmark index is down 0.5% to 7,331.5 points. Four ASX shares that are not letting that hold them back a...

Telix Pharmaceuticals (TLX) has received approval from the Australian drug watchdog for its prostate cancer imaging product The Therapeutic Goods Administrations (TGA) has granted Illuccix a broad clinical indication for certain patients w...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is charging higher, up 4.8% in morning trade to $6.96 per share. Below, we take a look at the latest regulatory approval that looks to be spurring investor interest in the ASX biotech sh...

Following Wall Street’s record levels on Friday, the ASX 200 rebounded to rise by 0.6% today. All sectors were in the green, except for Financials which fell by around 0.6%. The sector was dragged down by Westpac (ASX:WBC), which slumped by...

Telix Pharmaceuticals (ASX:TLX) has announced the first set of peer-reviewed results from the IPAX-1 Ph I/II study of TLX101 in combination with external beam radiation therapy in recurrent glioblastoma multiforme.

MoneyTalks is Stockhead’s regular recap of the stocks, sectors and trends that fund managers and analysts are looking at right now and in this edition we’re looking at big biotechs. Today we hear from James McDonald, portfolio manager of Pe...

The ASX 200 Health Index (XHJ) is up by 1.2% at the time of writing, compared to the broader index which is higher by 1%. Truscreen Group (ASX:TRU) was the best health stock performer, up by 38% after reporting key milestones including the...

Highlights The ASX 200 declined 0.9% by mid-session on Tuesday. Eight of the 11 sectors were in the red, barring energy, utilities and financials. The energy sector emerged as the biggest gainer as crude oil prices rose for a fifth st...

The ASX 200 health stocks index (XHJ) is falling sharply by 2.40% at the time of writing, compared to the broader ASX 200 index which fell by 0.60%. Imaging tech company, Mach7 Tech (ASX:M7T), jumped 6.5% higher this morning after receiving...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week The Healthc...

Markets were calm and collected on Thursday, as the ASX 200 climbed by more than 1% following a strong lead from Wall Street, and traded with little volatility throughout the session. Investors are still comfortable with the US Fed’s plans...

The S&P/ASX 200 Index (ASX: XJO) is on track to record a stellar gain on Thursday. In late afternoon trade, the benchmark index is up 1.1% to 7,376.4 points. Four ASX shares that have failed to follow the market higher today are listed...

The S&P/ASX 300 Index (ASX: XKO) is pushing higher today, following a rebound after Monday’s heavy loss. During mid-afternoon trade, the ASX 300 is up 1.21% to 7,386.5 points. Let’s take a look at which ASX companies are making headlin...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has plummeted today after the company announced news of its prostate cancer imaging investigational product, Illuccix. Illuccix is currently in the midst of the US Food and Drug Administ...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

15 15 2021 - A snapshot of the stocks on the move, featuring Telix Pharmaceuticals (ASX:TLX), Hotel Property Investments (ASX:HPI) & Calix (ASX:CXL).

15 Sep 2021 - Telix Pharmaceuticals (ASX:TLX) will contribute to a US therapy trial, designed to treat prostate cancer. Telix will supply its prostate imaging product Illuccix to …

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is up almost 6% in early trade. Below, we take a look at the ASX biotechnology company’s announcement of its approval to conduct a clinical trial. What did Telix announce? The Telix shar...

The ASX 200 health stocks index (XHJ) fell by 0.90% at the time of writing, compared to the broader ASX 200 index which fell by 0.40%. Medicinal cannabis play, Cronos Australia (ASX:CAU), has jumped by 19% in morning trading, after announci...

Telix Pharmaceuticals (ASX:TLX) has announced an exclusive commercial distribution agreement with Bologna-based RADIUS for its prostate cancer investigational imaging product Illuccix.

Wall Street snaps four-day losing streak In US stock markets, the S&P 500 rose by 0.23% and the Dow Jones climbed 0.76% – snapping their four-day losing streak. The tech-heavy Nasdaq however, inched lower by 0.07%. Energy stocks were th...

13 Sep 2021 - Telix Pharmaceuticals (ASX:TLX) has found an Italian distribution partner for its prostate imaging drug, Illuccix. The biotech firm says that Radius will be its comme…

Highlights Australian benchmark index, the ASX 200, traded higher by 0.3% by mid session. Five of the 11 sectors traded in green, while the energy and material sector gained the most. Sydney Airport topped the gainers’ list on the tak...

In morning trade, the Telix Pharmaceuticals Ltd (ASX: TLX) share price is on the rise. At the time of writing, the biopharmaceutical company’s shares are up 3% to $6.52. Why is the Telix share price rising today? Investors have been biddin...

Telix Pharmaceuticals (ASX:TLX) has announced that the last patient has been imaged in a phase one clinical study of the company's investigational prostate cancer imaging product TLX591-CDx.

In the spirit of the recently-concluded Olympics and ongoing Paralympics, congratulations to the backers of the radiopharmaceuticals group for a record-breaking performance after listing this week. In raising $92 million, Clarity (ASX:CU6)...

Highlights  ASX-listed healthcare companies rarely fail to bring joy to the market participants, with a few of them providing outstanding returns in the last couple of months. Rhinomed, IDT Australia, and Prescient lead the way with ou...

Clarity Pharmaceuticals (ASX:CU6) has become one of the biggest biotech IPOs in recent memory and yesterday, it gained on debut. The company raised $92 million at $1.40 per share and it rose as much as 22% on its debut. It is the third comp...

Highlights Actinogen Medical has completed the global grant process for Xanamem with the official notification for the grant of its patent application in Brazil. Althea’s Canadian subsidiary, Peak Processing Solutions, has entered into...

Highlights Investing in renewable energy and clean energy ETFs could be a lucrative way to combat climate change. ETFs allow investors to invest in a particular sector, index, or commodity rather than a specific company. Various excha...

Ikwezi Mining (ASX:IKW) topped the latest Running Hot list with a 14-day RSI of 82, after two straight weeks where lithium stocks dominated. Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength I...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Telix Pharmaceuticals Ltd (ASX: TLX) shares continue its upward trajectory, jumping 6% today. Can Telix shares keep lifting the bar?  Telix is a radiopharmaceutical company established and listed on ASX in 2017. Wait, what does it do? It is...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is soaring on the back of the company’s earnings for the first half of 2021. Right now, the Telix share price is $6.94, 6.77% higher than it was at yesterday’s close. Telix share price j...

Telix Pharmaceuticals (ASX:TLX) has announced new collaborations and studies of its investigational technologies.

While today was a better day for the ASX than the past two days, the bourse still finished slightly in the red After dropping by nearly 1% yesterday, the ASX 200 traded slightly higher for most of the day but closed 7,502 points, which was...

The ASX 200 fought back from a slow start to finish 0.12% lower in Wednesday trade, as local stocks struggle for traction after hitting new record highs this month. The major banks helped to drag the index higher, as the ASX 200 Financials...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has been a very strong performer on Wednesday. The molecularly targeted radiation (MTR) focused biopharmaceutical company’s shares have jumped 7% to $6.53 today. This means the Telix sha...

Highlights Incannex Healthcare has filed a registration statement for a planned IPO (initial public offering), seeking to be listed on NASDAQ under the ‘IXHL’ ticker. Telix has commenced two new studies to assess the potential utility...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...